title: Salivary and lacrimal gland dysfunction (sicca syndrome) after radioiodine therapy.
abstract: Salivary gland dysfunction has been described in patients undergoing radioiodine therapy but associated lacrimal gland dysfunction (sicca syndrome) has never been reported. We conducted a prospective cohort study with follow-up for up to 3 y in a tertiary care university center to determine the prevalence of sicca syndrome in patients after high-dose radioiodine treatment.
  
  
  METHODS
  From January 1990 to December 1995, all patients undergoing radioiodine therapy (n = 79) with a standard dose of 925 MBq to 18.5 GBq (25-500 mCi) were interviewed using a standardized questionnaire to determine subjective ocular and oral dryness and were examined for objective lacrimal and salivary gland dysfunction.
  
  
  RESULTS
  After radioiodine treatment, 32.9% of the patients reported subjective xerostomia and 25.3% reported subjective xerophthalmia in the first year of follow-up. Xerostomia persisted to the second year of follow-up in 20.3% of cases and was still present >3 y after the last dose of radioiodine in 15.2% of cases. Xerophthalmia persisted to the second year of follow-up in 17.7% of cases and was still present in the third year of follow-up in 13.9% of cases. Severe xerostomia occurred in 4 patients. Reduced salivary and lacrimal gland function was documented in 40 (50.6%) and 14 (17.7%) of the 79 cases, respectively, in the first year of follow-up. Objective xerostomia persisted in 13.9% of cases to the second year of follow-up and was still present in all patients >3 y after the last radioiodine application. Keratoconjunctivitis sicca persisted in 11 patients (13.9%) to the second year of follow-up but was only present in 6 patients (7.6%) >3 y after the last radioiodine application. Additionally, 28/79 patients (35.4%) who had a normal salivary gland scintigraphy previously showed reduced salivary gland function in the third year of follow-up. No significant dependence on cumulative treatment was found for objective xerostomia or xerophthalmia, but doses >11.1 GBq (300 mCi) were related to stage 3 dysfunction on salivary gland scintigraphy.
  
  
  CONCLUSIONS
  Salivary and lacrimal gland dysfunction (sicca syndrome) is relatively frequent after radioiodine therapy. In most cases this is a transient side effect, but in some patients it may persist for a long period or appear late.
authors.affiliation: Department of Internal Medicine, Vall d'Hebron General Teaching Hospital, Barcelona, Spain.
authors.forename: R
authors.initials: R
authors.lastname: Solans
authors.forename: J A
authors.initials: JA
authors.lastname: Bosch
authors.forename: P
authors.initials: P
authors.lastname: Galofré
authors.forename: F
authors.initials: F
authors.lastname: Porta
authors.forename: J
authors.initials: J
authors.lastname: Roselló
authors.forename: A
authors.initials: A
authors.lastname: Selva-O'Callagan
authors.forename: M
authors.initials: M
authors.lastname: Vilardell
mesh_terms: D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D005260:Female; D006801:Humans; D007457:Iodine Radioisotopes / Q000009:adverse effects* / Q000627:therapeutic use; D007765:Lacrimal Apparatus / Q000528:radiation effects*; D008297:Male; D008875:Middle Aged; D011832:Radiation Injuries; D011877:Radionuclide Imaging; D011879:Radiotherapy Dosage; D012469:Salivary Glands / Q000000981:diagnostic imaging / Q000528:radiation effects*; D012859:Sjogren's Syndrome / Q000175:diagnosis / Q000209:etiology*; D013964:Thyroid Neoplasms / Q000532:radiotherapy*; D014985:Xerophthalmia / Q000175:diagnosis; D014987:Xerostomia / Q000175:diagnosis
chemical_list: D007457:Iodine Radioisotopes